Sustained release tablet containing at least 95 percent theophyl

Details Sustained release tablet containing at least 95 percent theophyl Sustained release tablet containing at least 95 percent theophyl

1982-12-21

1984-08-14

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Identification or warning feature

Taste or smell or chemical irritation to the eye, nose, or...

424 19, 424 22, 424253, A61K 920, A61K 922, A61K 926, A61K 3152

Patent

active

044656602

ABSTRACT:
Non-disintegrating theophylline tablets having a pair of opposing substantially planar surfaces and a very thin cross-section have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production.

REFERENCES:
patent: 2980589 (1961-04-01), de Grunigen
patent: 3062720 (1962-11-01), Costello
patent: 3065143 (1962-11-01), Christenson et al.
patent: 3079303 (1963-02-01), Raff et al.
patent: 3080294 (1963-03-01), Shepard
patent: 3108046 (1963-10-01), Harbit
patent: 3133863 (1964-05-01), Tansey et al.
patent: 3147187 (1964-09-01), Playfair
patent: 3148124 (1964-09-01), Gaunt
patent: 3279995 (1966-10-01), Reid
patent: 3279998 (1966-10-01), Raff et al.
patent: 3344029 (1967-09-01), Berger
patent: 3402240 (1968-09-01), Cain et al.
patent: 3424842 (1969-01-01), Nurnberg
patent: 3456049 (1969-07-01), Hotko et al.
patent: 3507952 (1970-04-01), Rednick et al.
patent: 3622677 (1971-11-01), Short et al.
patent: 3632778 (1972-01-01), Sheth et al.
patent: 3639169 (1972-02-01), Broeg et al.
patent: 3641236 (1972-02-01), Coppen et al.
patent: 3773920 (1973-11-01), Nakamoto et al.
patent: 3782993 (1974-01-01), Rothgang et al.
patent: 3852421 (1974-12-01), Koyanagi et al.
patent: 3870790 (1975-03-01), Lowey et al.
patent: 3908003 (1975-09-01), Hirsh
patent: 3950508 (1976-04-01), Mony et al.
patent: 4017598 (1977-04-01), Ohno et al.
patent: 4167558 (1979-09-01), Sheth et al.
patent: 4209513 (1980-06-01), Torode et al.
patent: 4215104 (1980-07-01), Ullman et al.
patent: 4226849 (1980-10-01), Schor
patent: 4258027 (1981-03-01), Ullman et al.
patent: 4259314 (1981-03-01), Lowey
patent: 4264573 (1981-04-01), Powell et al.
patent: 4361545 (1982-11-01), Powell et al.
Lachman et al., The Theory and Practice of Industrial Pharmacy, 2nd Ed., (1976), Lea & Febiger, Philadelphia, PA., pp. 321-358 (Tablets), 439-465, (Sustained Action Dosage Forms).
Chem. Abs. 95:175586j, Benedikt, Asthma-Ther. Theophyllin Optim. Blutspiegel-Bestimm., Arbeitsgespraech, pp. 23-36, (1980).
Chem. Abs. 95:175666k, Sybrecht, Asthma-Ther. Theophyllin Optim. Blutspiegel-Bestimm., Arbeitsgespraech, pp. 108-121, (1980).
Chem. Abs. 94:20311w, Upton et al., J. Pharmacokinet. Biopharm., 8(2), 131-149, (1980).
Chem. Abs. 94:20319e, Upton et al., J. Pharmacokinet. Biopharm., 8(3), 229-242, (1980).
Chem. Abs. 94:90146v, Barrett, Curr. Ther. Res., 28 (5, Sect. 1), 669-681, (1980).
Chem. Abs. 93:12993j, Svedmyr et al., Curr. Med. Res. Opin., 6 (Suppl. 6), 40-44, (1979).
Chem. Abs. 93:12994k, Jonkman et al., Curr. Med. Res. Opin., 6 (Suppl. 6), 71-76, (1979).
Chem. Abs. 93:13041j, Trembath et al., Br. J. Clin. Pharmacol., 9(4), 365-369, (1980).
Chem. Abs. 93:31668y, Lipman, Mod. Med. Asia, 16(2), 59-60, (1980).
Chem. Abs. 93:31686c, French et al., Curr. Med. Res. Opin., 6 (Suppl. 6), 3-13, (1979).
Chem. Abs. 93:245364v, Meyer et al., Chest, 78(2), 300-303, (1980).
Chem. Abs. 92:11154d, Levitt et al., Curr. Ther. Res., 26(3), 311-316, (1979).
Chem. Abs. 92:11163f, Clements, Arch. Pharm. Chemi, Sci. Ed., 7(4), 132-134, (1979).
Chem. Abs. 92:153027p, Sansom et al., Eur. J. Clin. Pharmacol., 16(6), 417-421, (1979).
Chem. Abs. 92:203502n, Nielsen-Kudsk et al., Acta. Pharmacol. Toxicol., 46(3), 205-212, (1980).
Chem. Abs. 91:44449m, Plavsic et al., Lijec. Vjesn., 100(10), 610-612, (1978).
Chem. Abs. 91:78812q, Dasta et al., Am. J. Hosp. Pharm., 36(5), 613-617, (1979).
Chem. Abs. 91:128945h, Apold et al., Lancet, 1(8117), 667-668, (1979).
Chem. Abs. 90:12216w, Weinberger et al., N. Engl. J. Med., 299(16), 852-857, (1978).
Chem. Abs. 88:110416q, Gilenberg, Isr. Pharm. J., 20(5), 254-242, (1977).
Chem. Abs. 88:177130k, Spangler et al., Ann. Allergy, 40(1), 6-11, (1978).
Chem. Abs. 87:111184d, Hendeles et al., Am. J. Hosp. Pharm., 34(5), 525-527, (1977).
Chem. Abs. 87:157084z, Fixley et al., Am. Rev. Respir. Dis., 115 (6, Pt. 1), 955-962, (1977).
Chem. Abs. 87:157116m, Kristofferson et al., Acta. Pharm. Fenn., 86(2), 49-56, (1977).
Chem. Abs. 86:195084m, Kern et al., Drug Intell. Clin. Pharm., 11(3), 144-153, (1977).
Chem. Abs. 85:51681k, Sims et al., Br. J. Clin. Pharmacol., 3(1), 194-196, (1976).
Chem. Abs. 84:111563q, Welling et al., J. Clin. Pharmacol., 16(1), 43-50, (1976).
Chem. Abs. 82:103076b, Mitenko et al., Clin. Pharmacol. Ther., 16(4), 720-726, (1974).
Chem. Abs. 82:103072x, Graham et al., Aust. J. Pharm. Sci., 3(2), 66-68, (1974).

Affiliated with

Also associated with

Rating

Sustained release tablet containing at least 95 percent theophyl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release tablet containing at least 95 percent theophyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release tablet containing at least 95 percent theophyl will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-113817